Save on Recarbrio with Coupons, Discounts & Savings Programs


Start Saving Today!
Lower the Cost of Your Recarbrio Prescription
More great savings
View Related Generics
MEDICAL INFORMATION
Recarbrio Key Facts
What is Recarbrio?
Recarbrio is the brand name for imipenem, cilastatin, and relebactam and is available as an injection for IV use.
What dosages is Recarbrio available in?
Recarbrio is available as an IV injection that contains imipenem 500 mg (anhydrate equivalent), cilastatin 500 mg (free acid equivalent), and relebactam 250 mg (anhydrate equivalent).
What is Recarbrio used for?
Recarbrio is part of the penem antibiotic /beta lactamase inhibitor/renal dehydropeptidase inhibitor combinations class and treats urinary tract infection, bacterial infection, and gastrointestinal infection.
How does Recarbrio work?
Recarbrio is an antibiotic and is typically used in adults for treating serious infections including pneumonia that develops from the hospital or ventilator, complicated urinary tract infections (UTIs), and 3) complicated stomach infections.
How do I take Recarbrio?
Recarbrio is injected into your veins. It’s typically given to people in the hospital by a healthcare provider. But, depending on the infection, some people might be able to take Recarbrio at home under instructions from their provider.
Is it safe for me to take Recarbrio?
Recarbrio is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. Recarbrio is contraindicated in patients with a history of known
severe hypersensitivity to any component of Recarbrio.
Recarbrio Common Side Effects
Common side effects of Recarbrio:
- Increase in liver enzymes
- Anemia
- Diarrhea
- Low potassium blood levels
- Low sodium blood levels
Recarbrio Serious Side Effects
Serious side effects are rare with Recarbrio. Contact your doctor if you experience any of the following:
- Serious Allergic Reactions
- Seizures and Central Nervous System Reactions
- Potentially Serious Diarrhea
- Antibacterial Resistance
Effects of other drugs, drug classes and over-the-counter products on Recarbrio
The following medications may interact with Recarbrio:
- Ganciclovir: Avoid concomitant use
- Valproic Acid or Divalproex Sodium: Avoid concomitant use
Who makes Recarbrio?
Merck & Co., Inc.
Is Recarbrio safe in pregnancy?
Based on animal data, Recarbrio may cause fetal harm when administered to pregnant individuals. It should only be used during pregnancy if the benefit to you is worth the possible risk to your baby.
What is the generic name for Recarbrio?
Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
OUR CUSTOMERS VIEW
What Customers Love About Our Service
We want everyone to be happy and healthy, that’s what keeps us going. Read what some of them have to say about us.
Medicines Experts
Meet Our Medical Team
We are a broad skilled and passionate group of clinicians with experience of operating in health systems in the United Kingdom & United States. Providing excellent care and advice is at the heart of everything we do. You can read more about our medical team by visiting the medical team page or learn more about how we curate content by visiting our editorial process

























